CTOs on the Move


 
Sandoz, a Division of the Novartis group, is a global leader in the field of generic pharmaceuticals, offering a wide array of high-quality, affordable products that are no longer protected by patents.
  • Number of Employees: 250-1000
  • Annual Revenue: $500M-1 Billion
  • www.sandoz.com
  • 506 Carnegie Center Street 400
    Princeton, NJ USA 08540
  • Phone: 303.466.2400

Executives

Name Title Contact Details

Similar Companies

Imperative Care

Were reimagining how technology can solve #stroke`s unmet needs, enabling providers with the ability to raise the standard of care for patients.

APS Pharmacy

APS Pharmacy is a Palm Harbor, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aurobindo Pharma USA

Aurobindo USA is committed to delivering a broad portfolio of quality, affordable generic pharmaceuticals to pharmacists and patients. Since its first US ANDA approval in 2004, Aurobindo has expanded its portfolio to include more than 125 product families and 450 individual product packages, representing a wide range of therapeutic categories. Aurobindo has been recognized as the fastest growing pharmaceutical company in 2012,* and in early 2013, thanks to the ongoing support of our customers, became one of the top 10 pharmaceutical companies, brand or generic, in terms of total prescriptions dispensed.**

RESTAT

RESTAT is a West Bend, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diamedica

DiaMedica Inc., a development stage biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. The company`s lead clinical stage compound is DM199, a recombinant human protein known as rhKLK1, which is under phase I/II clinical trials for the treatment of Type 1 and Type 2 diabetes and associated complications. It is also developing DM204, a monoclonal antibody that is in preclinical development for the treatment of Type 2 diabetes; and DMDx, a chronic kidney disease assay to detect levels of the tissue kallikrein-1 protein in urine and to predict the rate of kidney disease progression. The company was formerly known as Diabex Inc. and changed its name to DiaMedica Inc. in February 2001. DiaMedica Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.